公开(公告)号：US11733243B2

公开(公告)日：2023-08-22

申请号：US16818854

申请日：2020-03-13

Applicant: Indiana University Research and Technology Corporation

Inventor： Craig Erickson ,  Debomoy Lahiri

IPC: A61K31/185 ,  G01N33/573 ,  A61K31/16

CPC classification number: G01N33/573 ,  A61K31/16 ,  A61K31/185 ,  G01N2333/4709 ,  G01N2333/48 ,  G01N2333/91205 ,  G01N2500/20 ,  G01N2800/2814 ,  G01N2800/52

Abstract: Studies in mouse models of Fragile X and preliminary studies in human youth demonstrate that ERK1/2 is biomarker useful to monitoring the treatment of people diagnosed with ASD. Results reported herein demonstrate that acamprosate has the ability to reduce levels of ERK1/2 activation associated with many of the symptoms of ASD. Accordingly, in addition to its utility as a diagnostic marker for ASD ERK1/2 activation levels can be used to monitor patients treated with acamprosate and to screen potentially therapeutic compounds.

公开(公告)号：US11478526B2

公开(公告)日：2022-10-25

申请号：US17094950

申请日：2020-11-11

Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

Inventor： Mythily Srinivasan ,  Debomoy Lahiri

IPC: A61K38/00 ,  A61K38/17 ,  A61K38/18 ,  C07K14/475 ,  C07K14/48 ,  C07K7/00 ,  A61K38/04 ,  A61K38/10 ,  A61K38/08 ,  A61K38/57 ,  A61K38/55 ,  C07K7/08 ,  C07K7/06 ,  C07K14/47 ,  A61P25/28 ,  A61P25/16 ,  A61P29/00 ,  C07K14/00 ,  C07K7/04 ,  C07K14/81

Abstract: The present disclosure provides pharmaceutical compositions comprising rationally designed peptide analogs of the p65-TAD binding region of GILZ to selectively sequester activated p65. Structural and functional analyses suggest that select GILZ analog (GA) bind p65-TAD with optimum affinity, exhibit an estimated half minimal lethal dose comparable to known peptide drugs and suppress Aβ1-42 induced cytotoxicity. Furthermore, the present disclosure provides uses and methods of using the pharmaceutical compositions, and uses and methods of using pharmaceutical formulations comprising the pharmaceutical compositions, for the treatment of neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS).

公开(公告)号：US20200225233A1

公开(公告)日：2020-07-16

申请号：US16818854

申请日：2020-03-13

Applicant: Indiana University Research and Technology Corporation

Inventor： Craig Erickson ,  Debomoy Lahiri

IPC: G01N33/573 ,  A61K31/185 ,  A61K31/16

Abstract: Studies in mouse models of Fragile X and preliminary studies in human youth demonstrate that ERK1/2 is biomarker useful to monitoring the treatment of people diagnosed with ASD. Results reported herein demonstrate that acamprosate has the ability to reduce levels of ERK1/2 activation associated with many of the symptoms of ASD. Accordingly, in addition to its utility as a diagnostic marker for ASD ERK1/2 activation levels can be used to monitor patients treated with acamprosate and to screen potentially therapeutic compounds.

公开(公告)号：US20160266120A1

公开(公告)日：2016-09-15

申请号：US15029596

申请日：2014-10-14

Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

Inventor： Craig Erickson ,  Debomoy Lahiri

IPC: G01N33/573 ,  A61K31/16

CPC classification number: G01N33/573 ,  A61K31/16 ,  A61K31/185 ,  G01N2333/4709 ,  G01N2333/48 ,  G01N2333/91205 ,  G01N2500/20 ,  G01N2800/2814 ,  G01N2800/52

Abstract: Studies in mouse models of Fragile X and preliminary studies in human youth demonstrate that ERK1/2 is biomarker useful to monitoring the treatment of people diagnosed with ASD. Results reported herein demonstrate that acamprosate has the ability to reduce levels of ERK1/2 activation associated with many of the symptoms of ASD. Accordingly, in addition to its utility as a diagnostic marker for ASD ERK1/2 activation levels can be used to monitory patients treated with acamprosate.

Abstract translation: 对脆性X的小鼠模型的研究和人类青年的初步研究表明ERK1 / 2是生物标志物可用于监测诊断为ASD的人的治疗。 本文报道的结果表明，acamprosate具有降低与许多ASD症状相关的ERK1 / 2激活水平的能力。 因此，除了其作为ASD ERK1 / 2的诊断标志物的作用之外，活化水平可用于用阿坎酸治疗的临床患者。